Sandoz Inc.
www.us.sandoz.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sandoz Inc.
Amgen Planning Pivotal Obesity Program For MariTide
Executives said during Amgen’s Q1 call that the company is “encouraged” by interim Phase II data for MariTide (AMG 133) in obesity, so it is designing Phase III trials and building manufacturing capacity.
Stock Watch: Novartis And The Changing Face Of Big Pharma
The sun shines over a sector with multi-blockbuster products in their prime. But clouds are looming, and highly innovative products that cannot replace the sales shortfalls could lead to a re-rating of the sector’s growth prospects.
Humira Market Erosion Is Continuing As Expected, AbbVie Says
With adalimumab biosimilar market share increasing in the US, AbbVie says revenue erosion is on its expected pace, driven mainly by discounts. Skyrizi, Rinvoq continue growth trajectories.
State Of Play: Does UK See Value In Generics and Biosimilars?
With 80% of medicines used by the UK’s National Health Service being off-patent drugs, the UK is nevertheless in need of a new economic framework to save waning competition due to low prices, delegates to a Westminster Health Forum conference heard from a Sandoz executive.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice